GlassScriptPhysician profile
Tami J Thornton
NPI 1841683323
$3,983.18
in general payments reported to CMS, 2019-2025
35 companies · $945 in 2025
The $945 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,041 · 2022: $494 · 2023: $576 · 2024: $927 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,419 · Education: $29.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.02 |
| Education | $29.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $931.26 | 2021-2025 | |
| Lilly USA, LLC | $554.02 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $505.78 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $431.48 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $225.88 | 2021-2025 | Rexulti |
| Mylan Specialty L.P. | $150.64 | 2021-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $143.87 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $142.11 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.95 | 2021-2025 | Tradjenta, Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $74.99 | 2021-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.47 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $65.59 | 2021-2023 | Steglatro, Belsomra |
| Idorsia Pharmaceuticals US INC | $41.36 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.10 | 2024-2025 | Caplyta |
| Abbott Laboratories | $39.81 | 2024 | Freestyle Libre 3 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39.42 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $37.53 | 2021 | |
| Viatris Specialty LLC | $35.30 | 2025 | Yupelri |
| Exact Sciences Corporation | $35.00 | 2025 | Cologuard Collection Kit |
| Acera Surgical, INC. | $32.64 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.02 | 2022 | |
| Amgen INC. | $25.52 | 2022 | |
| Eisai INC. | $23.90 | 2021 | |
| Vanda Pharmaceuticals INC. | $23.32 | 2024 | Hetlioz, Fanapt |
| Biohaven Pharmaceuticals, INC. | $22.96 | 2021 | |
| Astellas Pharma US INC | $22.65 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $19.52 | 2021 | |
| Currax Pharmaceuticals LLC | $17.00 | 2025 | Contrave |
| Collegium Pharmaceutical, INC. | $16.51 | 2023 | Belbuca |
| Kowa Pharmaceuticals America, INC. | $15.73 | 2024 | Livalo |
| Phathom Pharmaceuticals, INC. | $15.58 | 2024 | Voquezna |
| Electromed, INC. | $14.36 | 2025 | Smartvest |
| Biodelivery Sciences International, INC. | $14.31 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.17 | 2021 | |
| Esperion Therapeutics, INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Thornton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.